Basic Information
RNALocate ID: | RLID:02000603 |
RNA Symbol: | MEG3 |
Localization: | Nucleus |
RNA Information
RNA Name: | MEG3 |
RNA ID: | NCBI:55384|Ensembl:ENSG00000214548 |
RNA Category: | lncRNA |
Species: | Homo sapiens |
Alias: | FP504|GTL2|LINC00023|NCRNA00023|PRO0518|PRO2160|onco-lncRNA-83|prebp1 |
Localization Information
PubMed ID: | 22955988 |
Tissue/Cell Line: | Cell lines (GM12878|HeLaS3|HepG2)|Human umbilical vein endothelial cells |
Method: | Microarray |
Subcellular localization of known lncRNAs. Originally published in Genome Res. Derrien T, et al, 2012. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | We examined the subcellular location of a number of well-known lncRNAs (Fig. 8D). Unsurprisingly, the X-chromosome inactivating transcript XIST was extremely highly enriched in the nucleus for all cells we examined (with a maximum enrichment of 273-fold in the nucleus of GM12878 cells) (Fig. 8D). Other regulatory lncRNAs such as GAS5, LINC00568 (also known as ncRNA-a1), CYP4A22-AS1 (also known as ncRNA-a3), MIAT, and MEG3 were nuclear enriched in at least two different cell types, consistent with their reported roles in gene regulation. Other transcripts, including the bifunctional transcript SRA1, which acts as both a regulatory RNA and a protein-coding sequence, have more variable subcellular location depending on cell type. As reported previously, the H19 transcript is consistently enriched in the cytoplasm, especially when comparing with the chromatin fraction (cytoplasmic/chromatin enrichment 167-fold). |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:02000599 | Cytoplasm | Hepatoma cells | 21625215 |
RLID:02000600 | Endoplasmic reticulum | Human myelogenous leukemia cell line (K-562) | 21613539 |
RLID:02000601 | Nucleus | Cell line (BT-549) | 26205790 |
RLID:02000602 | Nucleus | HeLa cells | 31107149 |
RLID:02000604 | Nucleus | Lung fibroblasts | 25630241 |
RLID:02001151 | Cytoplasm | Human lens epithelial cells (SRA01/04) | 32841649 |
RLID:02001152 | Nucleus | Human lens epithelial cells (SRA01/04) | 32841649 |
RLID-D:12005230 | Exosome | Serum |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | MEG3 | Phaeochromocytoma | MNDR-E-LNC-17886 |
MNDR | MEG3 | Renal fibrosis | MNDR-E-LNC-17887 |
MNDR | MEG3 | Tongue squamous cell carcinoma | MNDR-E-LNC-17888 |
MNDR | MEG3 | Oral squamous cell carcinoma | MNDR-E-LNC-17889 |
MNDR | MEG3 | Myelodysplastic syndrome | MNDR-E-LNC-17890 |
MNDR | MEG3 | Prostate cancer | MNDR-E-LNC-17891 |
MNDR | MEG3 | Hirschsprung disease | MNDR-E-LNC-17892 |
MNDR | MEG3 | Gastric cancer | MNDR-E-LNC-17893 |
MNDR | MEG3 | Pre-eclampsia | MNDR-E-LNC-17894 |
MNDR | MEG3 | Bladder cancer | MNDR-E-LNC-17895 |
MNDR | MEG3 | Huntington disease | MNDR-E-LNC-17896 |
MNDR | MEG3 | Cardiovascular disease | MNDR-E-LNC-17897 |
MNDR | MEG3 | Lung cancer | MNDR-E-LNC-17898 |
MNDR | MEG3 | Endometrial cancer | MNDR-E-LNC-17899 |
MNDR | MEG3 | Metabolic syndrome | MNDR-E-LNC-17900 |
MNDR | MEG3 | Breast cancer | MNDR-E-LNC-17901 |
MNDR | MEG3 | Cancer | MNDR-E-LNC-17902 |
MNDR | MEG3 | Ventricular septal defect | MNDR-E-LNC-17903 |
MNDR | MEG3 | Thyroid cancer | MNDR-E-LNC-17904 |
MNDR | MEG3 | Clinical nonfunctioning pituitary adenoma | MNDR-E-LNC-17905 |
MNDR | MEG3 | Pancreatic cancer | MNDR-E-LNC-17906 |
MNDR | MEG3 | Pancreatic endocrine carcinoma | MNDR-E-LNC-17907 |
MNDR | MEG3 | Pancreatic neuroendocrine tumor | MNDR-E-LNC-17908 |
MNDR | MEG3 | Melanoma | MNDR-E-LNC-17909 |
MNDR | MEG3 | Atherosclerosis | MNDR-E-LNC-17910 |
MNDR | MEG3 | Vulva squamous cell carcinoma | MNDR-E-LNC-17911 |
MNDR | MEG3 | Epithelial ovarian cancer | MNDR-E-LNC-17912 |
MNDR | MEG3 | Nephroblastoma | MNDR-E-LNC-17913 |
MNDR | MEG3 | Colon cancer | MNDR-E-LNC-17914 |
MNDR | MEG3 | Ovarian cancer | MNDR-E-LNC-17915 |
MNDR | MEG3 | Hemangioma | MNDR-E-LNC-17916 |
MNDR | MEG3 | Kidney cancer | MNDR-E-LNC-17917 |
MNDR | MEG3 | Carcinoma endometrial | MNDR-E-LNC-17918 |
MNDR | MEG3 | Laryngeal squamous cell cancer | MNDR-E-LNC-17919 |
MNDR | MEG3 | Glioblastoma | MNDR-E-LNC-17920 |
MNDR | MEG3 | Glioma | MNDR-E-LNC-17921 |
MNDR | MEG3 | Chronic obstructive pulmonary disease | MNDR-E-LNC-17922 |
MNDR | MEG3 | Gallbladder cancer | MNDR-E-LNC-17923 |
MNDR | MEG3 | Embryonal rhabdomyosarcoma | MNDR-E-LNC-17924 |
MNDR | MEG3 | Osteosarcoma | MNDR-E-LNC-17925 |
MNDR | MEG3 | Pancreatic ductal adenocarcinoma | MNDR-E-LNC-17926 |
MNDR | MEG3 | Meningioma | MNDR-E-LNC-17927 |
MNDR | MEG3 | Liver cancer | MNDR-E-LNC-17928 |
MNDR | MEG3 | Choriocarcinoma | MNDR-E-LNC-17929 |
MNDR | MEG3 | Gastric adenocarcinoma | MNDR-E-LNC-17930 |
MNDR | MEG3 | Esophagus squamous cell carcinoma | MNDR-E-LNC-17931 |
MNDR | MEG3 | Non-functioning pituitary adenoma | MNDR-E-LNC-17932 |
MNDR | MEG3 | Lung squamous cell carcinoma | MNDR-E-LNC-17933 |
MNDR | MEG3 | Carcinoma lung non-small-cell | MNDR-E-LNC-17934 |
MNDR | MEG3 | Lung adenocarcinoma | MNDR-E-LNC-17935 |
MNDR | MEG3 | Thyroid carcinoma | MNDR-E-LNC-17936 |
MNDR | MEG3 | Papillary thyroid cancer | MNDR-E-LNC-17937 |
MNDR | MEG3 | Bladder urothelial carcinoma | MNDR-E-LNC-17938 |
MNDR | MEG3 | Valvulopathy | MNDR-E-LNC-17939 |
MNDR | MEG3 | Liver disease | MNDR-E-LNC-17940 |
MNDR | MEG3 | Cervical cancer | MNDR-E-LNC-17941 |
MNDR | MEG3 | Renal cell carcinoma | MNDR-E-LNC-17942 |
MNDR | MEG3 | Clear cell renal cell carcinoma | MNDR-E-LNC-17943 |
MNDR | MEG3 | Cholangiocarcinoma | MNDR-E-LNC-17944 |
MNDR | MEG3 | Myelofibrosis | MNDR-E-LNC-17945 |
MNDR | MEG3 | Esophageal cancer | MNDR-E-LNC-17946 |
MNDR | MEG3 | Liver cirrhosis | MNDR-E-LNC-17947 |
MNDR | MEG3 | Head and neck squamous cell carcinoma | MNDR-E-LNC-17948 |
MNDR | MEG3 | Testicular germ cell cancer | MNDR-E-LNC-17949 |
MNDR | MEG3 | Functionless pituitary adenoma | MNDR-E-LNC-17950 |
MNDR | MEG3 | Gastric cardia adenocarcinoma | MNDR-E-LNC-17951 |
MNDR | MEG3 | Hypoxia-induced pulmonary hypertension | MNDR-E-LNC-17952 |
MNDR | MEG3 | Pulmonary hypertension | MNDR-E-LNC-17953 |
MNDR | MEG3 | Cerebrovascular disease | MNDR-E-LNC-17954 |
MNDR | MEG3 | Hepatocellular carcinoma | MNDR-E-LNC-17955 |
MNDR | MEG3 | Cervical carcinoma | MNDR-E-LNC-17956 |
MNDR | MEG3 | Intraductal papillary mucinous neoplasms of the pancreas | MNDR-E-LNC-17957 |
MNDR | MEG3 | Retinoblastoma | MNDR-E-LNC-17958 |
MNDR | MEG3 | Neuroblastoma | MNDR-E-LNC-17959 |
MNDR | MEG3 | Osteoarthritis | MNDR-E-LNC-17960 |
MNDR | MEG3 | Chronic myeloid leukemia | MNDR-E-LNC-17961 |
MNDR | MEG3 | Immune thrombocytopenia | MNDR-E-LNC-17962 |
MNDR | MEG3 | Acute myeloid leukemia | MNDR-E-LNC-17963 |
MNDR | MEG3 | Colorectal cancer | MNDR-E-LNC-17964 |
MNDR | MEG3 | Nasopharyngeal carcinoma | MNDR-E-LNC-17965 |
MNDR | MEG3 | Nasopharynx carcinoma | MNDR-E-LNC-17966 |
MNDR | MEG3 | Diabetes mellitus | MNDR-E-LNC-17967 |
MNDR | MEG3 | Multiple myeloma | MNDR-E-LNC-17968 |
MNDR | MEG3 | Type 1 diabetes mellitus | MNDR-E-LNC-17969 |
MNDR | MEG3 | Heroin dependence | MNDR-E-LNC-17970 |
MNDR | MEG3 | Ovarian epithelial cancer | MNDR-E-LNC-17971 |
MNDR | MEG3 | Esophageal squamous cell cancer | MNDR-E-LNC-17972 |
MNDR | MEG3 | Uterine cervical neoplasms | MNDR-E-LNC-17973 |
MNDR | MEG3 | Liver fibrosis | MNDR-E-LNC-17974 |
MNDR | MEG3 | Nasopharyngeal cancer | MNDR-E-LNC-17975 |
MNDR | MEG3 | Prostate | MNDR-E-LNC-17976 |
MNDR | MEG3 | Purpura thrombocytopenic | MNDR-E-LNC-17977 |
MNDR | MEG3 | Stroke | MNDR-E-LNC-17978 |
MNDR | MEG3 | T-cell lymphoblastic lymphoma | MNDR-E-LNC-17979 |
MNDR | MEG3 | Liver ischemia/reperfusion(i/r)injury | MNDR-E-LNC-17980 |
MNDR | MEG3 | Spiral artery remodeling | MNDR-E-LNC-17981 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABCB1 | Homo sapiens | RR00022756 |
TOP